News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies Welcomes Mr. Stef Koppelman as Its New General Scientific Advisor



7/19/2012 10:04:16 AM

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Mr. Stef Koppelman, PhD as General Scientific Advisor. As such, Stef will champion DBV’s research efforts and provide the Executive Committee with key advice and insight, notably on food allergens and scientific matters.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES